GenapSys is now a post-effective-date liquidation case being administered by Redwood Liquidating Co., with current activity centered on preserving estate litigation/removal rights and finishing claims administration rather than operating the sequencing business. The debtor filed chapter 11 on July 11, 2022, after a liquidity collapse at the Redwood City life-sciences company, which had developed semiconductor-based DNA sequencing technology but entered the case amid litigation pressure, failed prepetition financing and sale-investment efforts, and a workforce wind-down that included furloughs and layoffs shortly before filing, as described in the Russell first-day declarationDkt. 11.
The case began as an expedited value-preservation process. GenapSys reported approximately $230.3 million of secured debt and preferred equity financing, including a $30 million Oxford Finance secured term loan against substantially all assets, and sought chapter 11 relief to stabilize the estate, obtain DIP financing from Oxford, and pursue a rapid sale process with early milestones for sale procedures, final DIP approval, and completion of a sale, all set out in the Russell first-day declarationDkt. 11. The docket now reflects that the operating restructuring has moved past emergence into plan administration under Redwood Liquidating Co., with remaining work focused on claims review and retained causes of action.
Recent filings show the post-effective-date debtor still extending core estate-administration deadlines. On April 17, 2026, the court extended the administrative expense claim objection deadline to July 30, 2026, after no objections were filed to the requested extension, and the related April 22 hearing was cancelled as resolved by the and . Redwood then moved to further extend the deadline to remove civil actions to September 24, 2026, citing ongoing plan administration, claims analysis, and pursuit of retained causes of action; objections are due June 10, 2026, with a June 24, 2026 omnibus hearing scheduled by the and .
